{"id":"ascvs-prazosin","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Hypotension (from prazosin component)"}]},"_chembl":{"chemblId":"CHEMBL1558","moleculeType":"Small molecule","molecularWeight":"419.87"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AScVS (Autologous Stem Cell Vaccine System) is designed to activate the patient's own immune system to recognize and attack cancer cells. Prazosin, an alpha-1 blocker traditionally used for hypertension, is hypothesized to potentiate immune responses by modulating adrenergic signaling. The combination aims to improve anti-tumor immunity through dual mechanisms.","oneSentence":"AScVS is an autologous stem cell vaccine that stimulates immune responses against cancer, combined with prazosin, an alpha-1 adrenergic antagonist that may enhance immune function.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:02:43.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (Phase 3 indication under investigation)"}]},"trialDetails":[{"nctId":"NCT00753064","phase":"PHASE3","title":"AScVS and/ or Prazosin for Scorpion Envenomation","status":"COMPLETED","sponsor":"Haffkine Bio-Pharmaceutical Corporation Ltd.","startDate":"2006-09","conditions":"Scorpion Envenomation","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AScVS (Haffkine)","T. Prazosin (sun pharma)"],"phase":"phase_3","status":"active","brandName":"AScVS + Prazosin","genericName":"AScVS + Prazosin","companyName":"Haffkine Bio-Pharmaceutical Corporation Ltd.","companyId":"haffkine-bio-pharmaceutical-corporation-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AScVS is an autologous stem cell vaccine that stimulates immune responses against cancer, combined with prazosin, an alpha-1 adrenergic antagonist that may enhance immune function. Used for Advanced or metastatic solid tumors (Phase 3 indication under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}